← Drug database

Pioglitazone Krka (pioglitazone)

Generic
Region
🇪🇺 EU
Active substance
pioglitazone
Company
KRKA tovarna zdravil d.d. Novo mesto
Status
Withdrawn
Therapeutic area
Diabetes Mellitus, Type 2
EU approval
Wed 21 Mar 2012
Designations
Generic
Application
EMEA/H/C/002453
ATC
A10BG03
Official record
www.ema.europa.eu

Indication

Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below: as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance; as dual oral therapy in combination with - a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea; Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus in adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Pioglitazone Krka

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.